[Clinical and biological predictors of ketamine response in treatment-resistant major depression: Review].
OBJECTIVE
The aim of this review was to determine the clinical and biological predictors of the ketamine response.


METHODS
A systematic research on PubMed and PsycINFO database was performed without limits on year of publication.


RESULTS
The main predictive factors of ketamine response, which were found in different studies, were (i) a family history of alcohol dependence, (ii) unipolar depressive disorder, and (iii) neurocognitive impairments, especially a slower processing speed. Many other predictive factors were identified, but not replicated, such as personal history of alcohol dependence, no antecedent of suicide attempt, anxiety symptoms. Some biological factors were also found such as markers of neural plasticity (slow wave activity, brain-derived neurotrophic factor Val66Met polymorphism, expression of Shank 3 protein), other neurologic factors (anterior cingulate activity, concentration of glutamine/glutamate), inflammatory factors (IL-6 concentration) or metabolic factors (concentration of B12 vitamin, D- and L-serine, alterations in the mitochondrial β-oxidation of fatty acids). This review had several limits: (i) patients had exclusively resistant major depressive episodes which represent a sub-type of depression and not all depression, (ii) response criteria were more frequently assessed than remission criteria, it was therefore difficult to conclude that these predictors were similar, and finally (iii) many studies used a very small number of patients.


CONCLUSIONS
In conclusion, this review found that some predictors of ketamine response, like basal activity of anterior cingulate or vitamin B12 concentration, were identical to other therapeutics used in major depressive episode. These factors could be more specific to the major depressive episode and not to the ketamine response. Others, like family history of alcohol dependence, body mass index, or D- and L-serine were different from the other therapeutics. Neurocognitive impairments like slower speed processing or alterations in attention tests were also predictive to a good response. These predictive factors could be more specific to ketamine. With these different predictor factors (clinical and biological), it could be interesting to develop clinical strategies to personalize ketamine's administration.
Service de psychiatrie adulte, hôpital Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France. Electronic address: brunoromeo@hotmail.fr.
B
B
Romeo
Service de psychiatrie adulte, hôpital Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
W
W
Choucha
Service de psychiatrie adulte, hôpital Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Inserm U 1127, CNRS, UMR 7225, UMR S 1127, institut du cerveau et de la moelle (ICM), social and affective neuroscience (SAN) laboratory, Sorbonne Universités, UPMC université Paris 06, 75013 Paris, France.
P
P
Fossati
Service de psychiatrie adulte, hôpital Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Inserm U 1127, CNRS, UMR 7225, UMR S 1127, institut du cerveau et de la moelle (ICM), social and affective neuroscience (SAN) laboratory, Sorbonne Universités, UPMC université Paris 06, 75013 Paris, France.
J-Y
JY
Rotge
D000928:Antidepressive Agents / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy; D061218:Depressive Disorder, Treatment-Resistant / Q000188:drug therapy* / Q000235:genetics / Q000523:psychology; D015870:Gene Expression; D006801:Humans; D007649:Ketamine / Q000627:therapeutic use*; D009483:Neuropsychological Tests; D011379:Prognosis; D016896:Treatment Outcome
D000928:Antidepressive Agents; D007649:Ketamine
Facteurs prédictifs de réponse; Ketamine; Kétamine; Major depressive episode; Predictors response; Épisodes dépressifs majeurs